BNP Paribas Financial Markets Decreases Stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

BNP Paribas Financial Markets cut its holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 16.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 127,679 shares of the biopharmaceutical company's stock after selling 25,571 shares during the quarter. BNP Paribas Financial Markets owned approximately 0.11% of Catalyst Pharmaceuticals worth $2,665,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of the business. Steward Partners Investment Advisory LLC acquired a new position in Catalyst Pharmaceuticals in the 4th quarter valued at about $27,000. Farther Finance Advisors LLC lifted its stake in shares of Catalyst Pharmaceuticals by 125.1% during the 4th quarter. Farther Finance Advisors LLC now owns 2,690 shares of the biopharmaceutical company's stock worth $56,000 after purchasing an additional 1,495 shares during the period. Wilmington Savings Fund Society FSB acquired a new stake in shares of Catalyst Pharmaceuticals during the fourth quarter worth $65,000. KBC Group NV boosted its holdings in shares of Catalyst Pharmaceuticals by 48.8% during the fourth quarter. KBC Group NV now owns 4,699 shares of the biopharmaceutical company's stock worth $98,000 after purchasing an additional 1,542 shares during the last quarter. Finally, Quarry LP purchased a new stake in shares of Catalyst Pharmaceuticals in the fourth quarter valued at $104,000. 79.22% of the stock is owned by hedge funds and other institutional investors.

Catalyst Pharmaceuticals Trading Down 0.5%

NASDAQ:CPRX traded down $0.12 during trading hours on Wednesday, hitting $24.56. 70,348 shares of the stock traded hands, compared to its average volume of 1,101,932. The firm has a 50 day moving average price of $23.37 and a 200 day moving average price of $22.51. The firm has a market cap of $3.00 billion, a price-to-earnings ratio of 20.85, a PEG ratio of 3.31 and a beta of 0.70. Catalyst Pharmaceuticals, Inc. has a fifty-two week low of $14.75 and a fifty-two week high of $26.16.

Analysts Set New Price Targets

A number of analysts have issued reports on CPRX shares. StockNews.com raised Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Friday, February 28th. Baird R W raised shares of Catalyst Pharmaceuticals to a "strong-buy" rating in a research report on Monday, February 3rd. HC Wainwright reaffirmed a "buy" rating and set a $35.00 price target on shares of Catalyst Pharmaceuticals in a research report on Friday, February 28th. Robert W. Baird lifted their price target on shares of Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the company an "outperform" rating in a report on Monday, March 3rd. Finally, Stephens reaffirmed an "overweight" rating and issued a $33.00 target price on shares of Catalyst Pharmaceuticals in a research report on Thursday, February 27th. Seven equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Buy" and an average target price of $32.29.

Insider Buying and Selling at Catalyst Pharmaceuticals

In other Catalyst Pharmaceuticals news, insider Brian Elsbernd sold 62,975 shares of the firm's stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $22.98, for a total value of $1,447,165.50. Following the sale, the insider now owns 188,564 shares of the company's stock, valued at $4,333,200.72. This trade represents a 25.04% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Gary Ingenito sold 200,000 shares of the firm's stock in a transaction that occurred on Tuesday, May 13th. The stock was sold at an average price of $23.68, for a total value of $4,736,000.00. Following the completion of the sale, the insider now owns 68,873 shares of the company's stock, valued at $1,630,912.64. This represents a 74.38% decrease in their position. The disclosure for this sale can be found here. Insiders sold 351,879 shares of company stock valued at $8,214,815 in the last quarter. Company insiders own 10.40% of the company's stock.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.